Patents Examined by Charanjit S. Aulakh
  • Fab I inhibitors
    Patent number: 7741339
    Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: June 22, 2010
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Walter J. Burgess, Dalia R. Jakas, William F. Huffman, William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
  • Water-soluble titanium alkoxide material
    Patent number: 7741486
    Abstract: A water soluble, water stable, titanium alkoxide composition represented by the chemical formula (OC6H6N)2Ti(OC6H2(CH2N(CH3)2)3-2,4,6)2 with a theoretical molecular weight of 792.8 and an elemental composition of 63.6% C, 8.1% H, 14.1% N, 8.1% O and 6.0% Ti.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: June 22, 2010
    Assignee: Sandia Corporation
    Inventor: Timothy J Boyle
  • Methods for preparing dehydrocavidine, dehydroapocavidine or their composition, their use and medicinal composition containing them
    Patent number: 7732458
    Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: June 8, 2010
    Inventors: Weidong Zhang, Hanxiong Li, Huiliang Li, Chuan Zhang, Runhui Liu, Juan Su, Xike Xu
  • Bis-triphenylsilyl compounds and their application on organic electronic device
    Patent number: 7728138
    Abstract: The present invention discloses a bis-triphenylsilyl compound and its applications as a host material, electron transport material, or hole transport material in an organic electronic device. The general structure of the bis-triphenylsilyl compound is as follows: where G represents any atomic moiety or single bond of the functional group selected from the group consisting of the following: aryl group, cyclene group, and heterocyclic ring group; and R1˜R32 represent substituents on aryl groups.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: June 1, 2010
    Assignee: National Tsing Hua University
    Inventors: Chien-Hong Cheng, Jin-Ju Lin, Hsiang-Jung Huang
  • Substituted quinolines for the treatment of cancer
    Patent number: 7728000
    Abstract: Compounds of formula G1-L-G2, where -G1 is a radical structurally close to cryptolepine, -L- is a single covalent bond or a covalent linking biradical selected from (CH2)rNR??(CH2)s and —(CH2)rNR??(CH2)sNR??(CH2)t—, —R?? and —R?? are radicals, same or different, selected from the group consisting of H and (C1-C3)-alkyl; r, s and t are an integer from 1 to 3 and, -G2 is H or a radical structurally close to -G1, are intercalators. They are compounds which intercalate between DNA base pairs, and are useful as therapeutic agents against cancer, as assess by an in vitro test of cytotoxicity with human leukemia cells Jurkat E6-1 and human carcinoma cells GLC-4. Preferred compounds are those where -G1 is bonded to -L- through a carbonyl amino and -L- is —(CH2)3NCH3(CH2)3 or —(CH2)2NCH3(CH2)sNCH3(CH2)2— where s =2 or 3.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: June 1, 2010
    Assignees: Crystax Pharmaceuticals, Universitat Politecnica de Catalunya, Consejo Superior de Investigactiones Cientificas
    Inventors: Juan Aymami Bofarull, Miquel Coll Capella, Amadeo Llebaria Soldevila, Isabel Navarro Muñoz
  • Azaperylenes as organic semiconductors
    Patent number: 7723521
    Abstract: A novel semiconductor device comprises an azaperylene organic semiconductor of the formula I wherein the substitutents are defined herein.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: May 25, 2010
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Frank Bienewald, Beat Schmidhalter, Ulrich Berens, Hans Jürg Kirner
  • Red electroluminescent compounds and organic electroluminescent device using the same
    Patent number: 7723520
    Abstract: The present invention relates to novel red phosphorescent compounds exhibiting high luminous efficiency, and organic electroluminescent devices comprising the same.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: May 25, 2010
    Assignee: SKC Haas Display Films Co., Ltd.
    Inventors: Hyun Kim, Young Jun Cho, Hyuck Joo Kwon, Bong Ok Kim, Sung Min Kim, Seung Soo Yoon
  • Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
    Patent number: 7723351
    Abstract: A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, is disclosed. Methods of making the conjugates and methods of treating mammals using the same are also disclosed.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: May 25, 2010
    Assignee: Enzon Pharmaceuticals, Inc.
    Inventors: Hong Zhao, Maria Belen Rubio, Dechun Wu, Puja Sapra
  • Organic light-emitting device and display apparatus
    Patent number: 7723915
    Abstract: An organic light-emitting device adapted for coating and having good emission efficiency and luminance. The organic light-emitting device employs an anode, a cathode, and a layer including an organic compound sandwiched between the anode and cathode. The layer containing the organic compound includes a bisfluorene compound represented by General Formula [1] below. wherein in Formula [1], A is a substituted or unsubstituted alkylene group, a substituted or unsubstituted cycloalkylene group, a substituted silylene group, a substituted germylene group, an oxygen atom, and a sulfur atom.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: May 25, 2010
    Assignee: Canon Kabushiki Kaisha
    Inventors: Yohei Iwasaki, Taiki Watanabe, Satoru Shiobara, Koichi Suzuki, Kazunori Ueno
  • Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
    Patent number: 7723536
    Abstract: Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: May 25, 2010
    Assignee: The Trustees Of The University of Pennsylvania
    Inventors: Amos B. Smith, III, Thomas J. Beauchamp, Matthew J. LaMarche, Yuping Qiu, Michael D. Kaufman, Hirokazu Arimoto, David R. Jones, Kaoru Kobayashi
  • Synthesis of sodium narcistatin and related compounds
    Patent number: 7709643
    Abstract: The present invention involves use of the compounds narciclasine (2a) and 7-deoxy-narciclasine (2c), which are obtained via isolation from the medicinal plant species Narcissus (Amaryllidaceae), as precursors in a novel synthesis method in which each of these compounds are selectively hydrogenated to produce trans-dihydronarciclasine (1a) and 7-deoxy-trans-dihydronarciclasine (1c). Also described herein is a novel synthesis method for producing sodium narcistatin (11) from narciclasine (2a). Further described herein are certain novel 3,4-cyclic phosphate prodrugs, including sodium-7-deoxynarcistatin (8), sodium-7-deoxy-transdihydronarcistatin (9), and sodium transdihydronarcistatin (10).
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: May 4, 2010
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University
    Inventors: George R. Pettit, Noeleen Melody
  • Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases
    Patent number: 7705013
    Abstract: A method of treating trypanosomiasis in a mammal, which entails administering to a mammal in need thereof an effective amount of medicinal producting comprising a plant extract comprising one or more compounds of formula (I).
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: April 27, 2010
    Assignees: Institut de Recherche pour le Developpement, Universite Nationale d'Asuncion
    Inventors: Maria Elena Ferreira, Alain Fournet, Antonieta Rojas De Arias, Reynald Hocquemiller, Erwan Poupon
  • Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents
    Patent number: 7705012
    Abstract: Compounds of Formula (I) are described in which the R1 group is as defined in the specification and includes the condensation of the camptothecin molecule in position 7 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors ?v?3 and ?v?5 and with selective cytotoxic activity on human tumour cell lines at micromolar concentrations.
    Type: Grant
    Filed: May 4, 2005
    Date of Patent: April 27, 2010
    Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Instituto Nazionale per lo Studio e la Cura Dei Tumori
    Inventors: Claudio Pisano, Giuseppe Giannini, Maria Ornella Tinti, Loredana Vesci, Domenico Alloatti, Sergio Penco, Alma Dal Pozzo, Ni Minghong, Sabrina Dallavalle, Lucio Merlini, Franco Zunino
  • Synthesis and crystalline forms of NPY5 antagonist
    Patent number: 7700611
    Abstract: The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1?-cyclohexane]-4?-carboxamide and novel salts, hydrates and polymorphs thereof.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: April 20, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Russell R. Ferlita, Yuji Haga, Makoto Ishikawa, Keisuke Kamei, Shinji Kato, Hisaki Kojima, Aaron Moment, Nobuaki Nonoyama, Nobuya Satake, Kazuki Shigemori, Toshihiro Wada, Yaling Wang, Steven A. Weissman, Robert M. Wenslow
  • Spiro-oxindole compounds and their uses as therapeutic agents
    Patent number: 7700641
    Abstract: This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: April 20, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Nagasree Chakka, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Duanjie Hou, Tom Hsieh, Rajender Kamboj, Shifeng Liu, Vandna Raina, Mehran Seid Bagherzadeh, Jianyu Sun, Shaoyi Sun, Serguei Sviridov
  • Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
    Patent number: 7700612
    Abstract: The present invention is related to 10,20-di-O ester derivatives of camptothecin and pharmaceutical formulations thereof. The compounds and pharmaceutical formulations of the present invention possess increased biological life span and bioavailability and reduced toxicity, while maintaining anti-cancer activity.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: April 20, 2010
    Assignee: Abraxis BioScience, LLC
    Inventors: Patrick Soon-Shiong, Neil P. Desai, Chunlin Tao, Cheng Zhi Yu
  • Small-molecule inhibitors of the androgen receptor
    Patent number: 7696227
    Abstract: The present invention provides a method of inhibiting an androgen receptor by administering a compound of Formula I: or a compound of Formula II: wherein R1, R2, R3 and R8 are each independently hydrogen or C1-6 alkyl. R4 is absent or is hydrogen, C1-6 alkyl or C1-6 alkyl-OH. R5 is hydrogen, C1-6 alkyl or —NR6R7. R6 and R7 are each independently hydrogen or C1-6 alkyl, or are combined with the nitrogen to which they are attached to form a heterocycloalkyl having from 5 to 7 ring members. L is a linker of C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene or C3-6 cycloalkylene. The compounds of Formula I include the salts, hydrates and prodrugs thereof. Each R9 is H, C1-6 alkyl, —OH or —O—C1-6 alkyl. The compounds of Formulas I and II include the salts, hydrates and prodrugs thereof. By administering the compound of Formula I or II, the method inhibits the androgen receptor.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: April 13, 2010
    Assignee: Regents of the University of California
    Inventors: Marc Diamond, Jeremy Jones, Adam Renslo
  • Visual function disorder improving agents
    Patent number: 7696194
    Abstract: The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of a visual function disorder associated with various eye diseases caused by damage, defects, degeneration and the like in the retinal or optic nerve.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: April 13, 2010
    Assignees: Senju Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation
    Inventors: Yoshiko Takayama, Yukuo Yoshida, Masayoshi Uehata
  • Organometallic complex and organic electroluminescent device using the same
    Patent number: 7687626
    Abstract: Provided are a highly efficient phosphorescent organometallic complex and an organic electroluminescent (EL) device using the same. The organometallic complex can be used in the formation of an organic layer of the organic EL device, and can emit light in a red wavelength range as a highly efficient phosphorescent material. The organic EL device using the organometallic complex can exhibit high brightness and a low driving voltage.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: March 30, 2010
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Das Rupasree Ragini, Hee-kyung Kim, O-hyun Kwon, Young-hun Byun, Joon-yong Park, Jung-bae Song, Eun-sil Han
  • Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
    Patent number: RE41226
    Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine polymitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: April 13, 2010
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria Ornella Tinti, Piero Chiodi, Arduino Arduini